XML 103 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)
2 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2023
USD ($)
Oct. 01, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Oct. 01, 2022
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Oct. 01, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jun. 30, 2022
USD ($)
reporting_unit
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2022
reporting_unit
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Finite-Lived Intangible Assets [Line Items]                                    
Asset impairments                               $ 54,000,000 $ 15,000,000 $ 234,000,000
Impairment of Intangible Asset, Finite Lived, Statement of Income or Comprehensive Income, Extensible Enumeration, Not Disclosed Flag                                 impairments impairments
Finite-lived intangible assets $ 4,753,000,000     $ 4,102,000,000                       4,753,000,000 $ 4,102,000,000  
Goodwill impairments                               493,000,000 824,000,000  
Goodwill 11,183,000,000     11,547,000,000                       11,183,000,000 11,547,000,000 $ 12,457,000,000
Accumulated goodwill impairment charges to date 5,497,000,000                             5,497,000,000    
Salix                                    
Finite-Lived Intangible Assets [Line Items]                                    
Goodwill impairments                               0 0  
Goodwill 3,159,000,000     $ 3,159,000,000                       3,159,000,000 $ 3,159,000,000 3,159,000,000
Dermatology                                    
Finite-Lived Intangible Assets [Line Items]                                    
Number of reporting units | reporting_unit                             2      
Uceris Foam                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of intangible assets                         $ 37,000,000     37,000,000    
Xifaxan Branded Products                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of intangible assets 0         $ 0                        
Finite-lived intangible assets $ 2,155,000,000                             $ 2,155,000,000    
Finite lived intangible assets, useful life 48 months                             48 months    
Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk | Salix                                    
Finite-Lived Intangible Assets [Line Items]                                    
Concentration risk, percentage                               80.00%    
Bausch + Lomb                                    
Finite-Lived Intangible Assets [Line Items]                                    
Number of reporting units | reporting_unit                       3            
Generics Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates 1.00%                             1.00%    
Reporting unit, impairment test, estimated cash flows, discount rate 10.25%                             10.25%    
Percentage of fair value in excess of carrying value                     40.00%              
Goodwill impairments $ 91,000,000                   $ 0              
Goodwill 227,000,000                             $ 227,000,000    
Dermatology Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates     0.00%     1.00% 1.00% 1.00% 1.00%   1.00% 1.00%   1.00% 1.00%      
Reporting unit, impairment test, estimated cash flows, discount rate     10.75%     10.50% 10.00% 9.00% 9.00%     10.00%   10.50% 9.00%      
Percentage of fair value in excess of carrying value               2.00% 10.00%           2.00%      
Goodwill impairments     $ 151,000,000       $ 83,000,000 $ 0 $ 0   $ 469,000,000     $ 119,000,000        
Reporting unit, impairment test, estimated cash flows, change in discount rate             1.00%         1.00%            
Goodwill 329,000,000   $ 329,000,000     $ 480,000,000               $ 480,000,000   329,000,000    
Vision Care and Consumer Products, Pharmaceuticals and Surgical Reporting Units                                    
Finite-Lived Intangible Assets [Line Items]                                    
Percentage of fair value in excess of carrying value                   45.00%                
Goodwill impairments                   $ 0                
Vision Care, Surgical and Pharmaceuticals Reporting Units | Bausch + Lomb                                    
Finite-Lived Intangible Assets [Line Items]                                    
Percentage of fair value in excess of carrying value   25.00%   25.00%     25.00%         25.00%         25.00%  
Goodwill impairments   $ 0   $ 0               $ 0            
Salix Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates           2.50%               2.50%        
Percentage of fair value in excess of carrying value           5.00%               5.00%        
Goodwill impairments           $ 0                        
Neurology Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates     (2.50%) (2.50%)                         (2.50%)  
Reporting unit, impairment test, estimated cash flows, discount rate     10.50% 10.25%                         10.25%  
Goodwill impairments     $ 251,000,000   $ 622,000,000                          
Goodwill $ 1,177,000,000   $ 1,192,000,000 $ 1,439,000,000                       $ 1,177,000,000 $ 1,439,000,000  
International Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates 3.00%                             3.00%    
Reporting unit, impairment test, estimated cash flows, discount rate 12.75%                             12.75%    
Percentage of fair value in excess of carrying value 75.00%                             75.00%    
Goodwill impairments $ 0                                  
Minimum | Generics Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates                     1.00%              
Reporting unit, impairment test, estimated cash flows, discount rate                     11.00%              
Minimum | Dermatology Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, estimated cash flows, discount rate                     9.00%              
Minimum | Vision Care and Consumer Products, Pharmaceuticals and Surgical Reporting Units                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates                   2.00%                
Reporting unit, impairment test, estimated cash flows, discount rate                   7.00%                
Minimum | Vision Care, Surgical and Pharmaceuticals Reporting Units | Bausch + Lomb                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates   2.00%   2.00%     2.00%         2.00%         2.00%  
Reporting unit, impairment test, estimated cash flows, discount rate   10.25%   9.50%     9.00%         9.00%         9.50%  
Minimum | Salix Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, estimated cash flows, discount rate           9.75%               9.75%        
Maximum | Generics Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates                     3.00%              
Reporting unit, impairment test, estimated cash flows, discount rate                     12.25%              
Maximum | Dermatology Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, estimated cash flows, discount rate                     10.00%              
Maximum | Vision Care and Consumer Products, Pharmaceuticals and Surgical Reporting Units                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates                   3.00%                
Reporting unit, impairment test, estimated cash flows, discount rate                   10.00%                
Maximum | Vision Care, Surgical and Pharmaceuticals Reporting Units | Bausch + Lomb                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, long-term growth rates   3.00%   3.00%     3.00%         3.00%         3.00%  
Reporting unit, impairment test, estimated cash flows, discount rate   11.50%   12.25%     11.50%         11.50%         12.25%  
Maximum | Salix Reporting Unit                                    
Finite-Lived Intangible Assets [Line Items]                                    
Reporting unit, impairment test, estimated cash flows, discount rate           10.00%               10.00%        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of intangible assets                                   88,000,000
Trade Names No Longer Used                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of intangible assets                               $ 8,000,000    
Discontinued Product Lines                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of intangible assets                               9,000,000 $ 5,000,000 23,000,000
Product brands                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of intangible assets                                 10,000,000 105,000,000
Finite-lived intangible assets $ 4,336,000,000     $ 3,644,000,000                       $ 4,336,000,000 $ 3,644,000,000  
Finite lived intangible assets, useful life 3 years                             3 years    
Product brands | Minimum                                    
Finite-Lived Intangible Assets [Line Items]                                    
Finite lived intangible assets, useful life 1 year                             1 year    
Product brands | Maximum                                    
Finite-Lived Intangible Assets [Line Items]                                    
Finite lived intangible assets, useful life 20 years                             20 years    
Unutilized IT Infrastructure Improvement Project                                    
Finite-Lived Intangible Assets [Line Items]                                    
Impairment of intangible assets                                   $ 18,000,000